Clinical trials: Atezolizumab
Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
The goal of this observational study is to evaluate how well first-line immunotherapy works and investigate its association with immune-related adverse events (irAEs) in Egyptian adults with unresectable hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable, Hepatocellular Carcinoma Metastatic
- Trial name
- NCT07904494
- Testing
- Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab
- Where
- 4 sites in Egypt
- Volunteers
- 294 people
- Sponsor
- Assiut University
MSI, ColoRectal Cancer
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity…
- Conditions
- MSI, ColoRectal Cancer, Chemotherapy, Resistance, APC
- Trial name
- NCT02982694
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in Belgium, Italy and 2 more
- Volunteers
- 46 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Bladder Cancer
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts.
- Trial name
- NCT02108652
- Testing
- Atezolizumab
- Where
- 77 sites in United States, Canada and 6 more
- Volunteers
- 310 people
- Sponsor
- Hoffmann-La Roche
Gastrointestinal Cancer, Cholangiocarcinoma
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
This study aims to find out: 1. The tolerability of Cabotamig (ARB202) in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2.
- Conditions
- Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer, Colorectal Adenocarcinoma
- Trial name
- NCT05411133
- Testing
- Cabotamig (ARB202)
- Where
- 3 sites in Australia, Hong Kong
- Volunteers
- 33 people
- Sponsor
- Arbele Pty Ltd
Carcinoma, Non-Small-Cell Lung
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC).
- Trial name
- Morpheus Lung (NCT03337698)
- Testing
- Atezolizumab, Cobimetinib, RO6958688
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Adult, Metastatic Cancer
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy
The TEMPLE study is a single-center prospective phase Ib and II trial to determine the safety, tolerability and efficacy of Atezolizumab given in combination with thiopurine therapy (6-mercaptopurine and 6-thioguanine) in…
- Trial name
- TEMPLE (NCT05276284)
- Testing
- Atezolizumab, 6-mercaptopurine, 6-thioguanine
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Kristoffer Rohrberg
Breast Cancer
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
- Trial name
- NCT04158258
- Testing
- Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine
- Where
- 30 sites in Argentina, Brazil and 8 more
- Volunteers
- 2,907 people
- Sponsor
- Hoffmann-La Roche
Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer.
- Conditions
- Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- NCT05312671
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Non-small Cell Lung Cancer, Neoplasm
Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI Study
This retrospective, single-center observational cohort study evaluates inflammatory-metabolic, cachexia-related, and computed tomography (CT)-derived body-composition markers in patients with metastatic non-small cell lung cancer…
- Trial name
- SARC-CTI (NCT07192926)
- Testing
- Immune Checkpoint Inhibitor-Based Therapy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 155 people
- Sponsor
- Ankara Etlik City Hospital
Melanoma, Head and Neck Squamous Cell Carcinoma
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
A Phase 1a/1b, multicenter, open-label, non-randomized, dose-escalation, and cohort expansion study to examine the DLTs, MTD, and RP2D of SB 11285 administered as an IV infusion in patients with advanced solid tumors.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
- Trial name
- NCT04096638
- Testing
- SB 11285, Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- invoX Pharma Limited
Hepatocellular Carcinoma (HCC)
The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death globally. This retrospective, multicentric study will be coordinated by Dr.
- Trial name
- MANIFEST-HCC (NCT06903663)
- Where
- 4 sites in Romania
- Volunteers
- 100 people
- Sponsor
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Carcinoma, Small Cell Lung
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage…
- Trial name
- NCT04308785
- Testing
- Atezolizumab, Tiragolumab
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites.
- Trial name
- NCT07895043
- Testing
- Alveltamig, Atezolizumab, ABBV-706
- Volunteers
- 80 people
- Sponsor
- AbbVie
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with…
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck
- Trial name
- NCT04504669
- Testing
- AZD8701, Durvalumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Malignant Melanoma
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
This study will evaluate the preliminary efficacy, safety, and pharmacokinetics of cobimetinib and atezolizumab in participants with advanced BRAF V600-wild type (WT), metastatic, or unresectable locally advanced melanoma who…
- Trial name
- NCT03178851
- Testing
- Atezolizumab, Cobimetinib
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
HCC - Hepatocellular Carcinoma
Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma
This study adopted a bidirectional cohort study design. On the one hand, the previous clinical data, treatment exposure and clinical endpoint events of the enrolled patients were retrospectively collected.
- Trial name
- NCT07610551
- Testing
- Unresectable HCC patients receiving SIRT-Y90 combined with atezolizumab and bevacizumab (including some patients who received only SIRT-Y90 treatment)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Air Force Military Medical University, China
NSCLC Stage IIIB~IV
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.
using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
- Trial name
- NCT04147351
- Testing
- Atezolizumab Injection; bevacizumab Injection
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- National Taiwan University Hospital
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
This phase I trial is to find out the best dose, possible benefits and/or side effects of NHS-IL12 given together with bintrafusp alfa and radiation therapy in treating patients with hormone receptor positive, HER2 negative…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic HER2 Negative Breast Adenocarcinoma
- Trial name
- NCT04756505
- Testing
- Bintrafusp Alfa, Immunocytokine NHS-IL12, Radiation Therapy
- Sponsor
- M.D. Anderson Cancer Center
Stage I Colon Cancer, Stage II Colon Cancer
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
This is a Phase II open-label trial of neoadjuvant immunochemotherapy with Atezolizumab and CAPOX followed by surgery and potentially adjuvant chemotherapy for patients with localized resectable pMMR adenocarcinoma of the colon…
- Conditions
- Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
- Trial name
- NICER (NCT05870800)
- Testing
- Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer…
- Trial name
- NCT06287775
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 43 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)